Tags

Type your tag names separated by a space and hit enter

The impact of patatin-like phospholipase domain-containing protein 3 polymorphism on hepatocellular carcinoma prognosis.
J Gastroenterol. 2013 Mar; 48(3):405-12.JG

Abstract

BACKGROUND

The single nucleotide polymorphism (SNP) rs738409 in patatin-like phospholipase domain-containing protein 3 (PNPLA3) is associated with hepatic fat accumulation and disease progression in patients with non-alcoholic fatty liver disease and alcoholic liver disease (ALD). This study was conducted to determine whether PNPLA3 rs738409 SNPs affect development and prognosis of hepatocellular carcinoma (HCC) in patients with various liver diseases.

METHODS

We enrolled 638 consecutive Japanese patients newly diagnosed with HCC between 2001 and 2010: 72 patients with hepatitis B virus (HBV), 462 with hepatitis C virus (HCV), and 104 with non-B non-C (NBNC).

RESULTS

NBNC patients exhibited large tumors of advanced TNM stages at HCC diagnosis, and had significantly poorer prognosis than HBV or HCV patients (P < 0.001 and <0.001, respectively; log-rank test). The G/G genotype of PNPLA3 rs738409 SNP had significantly higher distribution in NBNC patients (P < 0.001) and was significantly associated with higher body mass index (BMI) and an increased aspartate aminotransferase to platelet ratio index. No significant differences were observed in survival with differences in PNPLA3 SNP genotypes among the patients, although ALD patients with the G/G genotype of PNPLA3 SNP and low BMI had significantly poorer survival than those with high BMI (P = 0.028).

CONCLUSIONS

The G/G genotype of PNPLA3 rs738409 SNP was more frequently distributed, and associated with BMI and fibrosis among NBNC-HCC patients but not among HBV or HCV patients. These genotypes might affect HCC prognosis in ALD patients, but not in HBV, HCV, or NAFLD patients.

Authors+Show Affiliations

Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Okayama, 700-8558, Japan.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

22869157

Citation

Takeuchi, Yasuto, et al. "The Impact of Patatin-like Phospholipase Domain-containing Protein 3 Polymorphism On Hepatocellular Carcinoma Prognosis." Journal of Gastroenterology, vol. 48, no. 3, 2013, pp. 405-12.
Takeuchi Y, Ikeda F, Moritou Y, et al. The impact of patatin-like phospholipase domain-containing protein 3 polymorphism on hepatocellular carcinoma prognosis. J Gastroenterol. 2013;48(3):405-12.
Takeuchi, Y., Ikeda, F., Moritou, Y., Hagihara, H., Yasunaka, T., Kuwaki, K., Miyake, Y., Ohnishi, H., Nakamura, S., Shiraha, H., Takaki, A., Iwasaki, Y., Nouso, K., & Yamamoto, K. (2013). The impact of patatin-like phospholipase domain-containing protein 3 polymorphism on hepatocellular carcinoma prognosis. Journal of Gastroenterology, 48(3), 405-12. https://doi.org/10.1007/s00535-012-0647-3
Takeuchi Y, et al. The Impact of Patatin-like Phospholipase Domain-containing Protein 3 Polymorphism On Hepatocellular Carcinoma Prognosis. J Gastroenterol. 2013;48(3):405-12. PubMed PMID: 22869157.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The impact of patatin-like phospholipase domain-containing protein 3 polymorphism on hepatocellular carcinoma prognosis. AU - Takeuchi,Yasuto, AU - Ikeda,Fusao, AU - Moritou,Yuki, AU - Hagihara,Hiroaki, AU - Yasunaka,Tetsuya, AU - Kuwaki,Kenji, AU - Miyake,Yasuhiro, AU - Ohnishi,Hideki, AU - Nakamura,Shinichiro, AU - Shiraha,Hidenori, AU - Takaki,Akinobu, AU - Iwasaki,Yoshiaki, AU - Nouso,Kazuhiro, AU - Yamamoto,Kazuhide, Y1 - 2012/08/07/ PY - 2012/06/03/received PY - 2012/07/09/accepted PY - 2012/8/8/entrez PY - 2012/8/8/pubmed PY - 2013/9/27/medline SP - 405 EP - 12 JF - Journal of gastroenterology JO - J. Gastroenterol. VL - 48 IS - 3 N2 - BACKGROUND: The single nucleotide polymorphism (SNP) rs738409 in patatin-like phospholipase domain-containing protein 3 (PNPLA3) is associated with hepatic fat accumulation and disease progression in patients with non-alcoholic fatty liver disease and alcoholic liver disease (ALD). This study was conducted to determine whether PNPLA3 rs738409 SNPs affect development and prognosis of hepatocellular carcinoma (HCC) in patients with various liver diseases. METHODS: We enrolled 638 consecutive Japanese patients newly diagnosed with HCC between 2001 and 2010: 72 patients with hepatitis B virus (HBV), 462 with hepatitis C virus (HCV), and 104 with non-B non-C (NBNC). RESULTS: NBNC patients exhibited large tumors of advanced TNM stages at HCC diagnosis, and had significantly poorer prognosis than HBV or HCV patients (P < 0.001 and <0.001, respectively; log-rank test). The G/G genotype of PNPLA3 rs738409 SNP had significantly higher distribution in NBNC patients (P < 0.001) and was significantly associated with higher body mass index (BMI) and an increased aspartate aminotransferase to platelet ratio index. No significant differences were observed in survival with differences in PNPLA3 SNP genotypes among the patients, although ALD patients with the G/G genotype of PNPLA3 SNP and low BMI had significantly poorer survival than those with high BMI (P = 0.028). CONCLUSIONS: The G/G genotype of PNPLA3 rs738409 SNP was more frequently distributed, and associated with BMI and fibrosis among NBNC-HCC patients but not among HBV or HCV patients. These genotypes might affect HCC prognosis in ALD patients, but not in HBV, HCV, or NAFLD patients. SN - 1435-5922 UR - https://www.unboundmedicine.com/medline/citation/22869157/The_impact_of_patatin_like_phospholipase_domain_containing_protein_3_polymorphism_on_hepatocellular_carcinoma_prognosis_ L2 - https://dx.doi.org/10.1007/s00535-012-0647-3 DB - PRIME DP - Unbound Medicine ER -